Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · Real-Time Price · USD
1.550
-0.010 (-0.64%)
At close: Jun 26, 2025, 4:00 PM
1.640
+0.090 (5.81%)
After-hours: Jun 26, 2025, 5:26 PM EDT
Q32 Bio Employees
As of December 31, 2024, Q32 Bio had 43 total employees, including 42 full-time and 1 part-time employees. The number of employees increased by 6 or 16.22% compared to the previous year.
Employees
43
Change (1Y)
6
Growth (1Y)
16.22%
Revenue / Employee
n/a
Profits / Employee
-$1,390,535
Market Cap
18.91M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 43 | 6 | 16.22% |
Dec 31, 2023 | 37 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
QTTB News
- 1 day ago - Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer - PRNewsWire
- 7 weeks ago - Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata - PRNewsWire
- 2 months ago - Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata - PRNewsWire
- 3 months ago - Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting - PRNewsWire
- 4 months ago - Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting - PRNewsWire
- 4 months ago - Q32 Bio to Participate in Upcoming March Investor Conferences - PRNewsWire